In many hematopoietic malignancies such as lymphomas and leukemias, aberrant differentiation is
However, the retroviral restoration of PU.1 expression has been shown to rescue myeloid differentiation of mutant progenitors and AML blasts.
The PU.1 protein contains three distinct functional domains (Fig. 1a) . The amino terminus contains both a highly acidic and a glutamine-rich transactivation domain . The carboxy-terminal region encompasses the evolutionarily conserved DNA-binding domain (also known as ETS domain) that contains approx. 85 amino acids (Klemsz, 1990) . The transactivation and ETS domains are linked by a PEST (P-proline, E-glutamic acid, S-serine, T-threonine) domain also referred to as the potential protein degradation domain (Rogers, 1986) . It has been demonstrated that transcription factor GATA-1 suppresses the myeloid gene expression program by inhibiting the PU.1 activity in a dose-dependent manner (Nerlov et al., 2000) . This inhibition takes place though a direct proteinprotein interaction wherein the C-terminal zinc finger of GATA-1 physically binds with the β3/β4 region in the DNA binding domain of PU.1 and displaces its coactivator c-Jun (Fig. 1b) . c-Jun acts as an important coactivator of PU.1 during the gene regulation of various myeloid promoters such as M-CSF receptor and macrosialin (Behre, 3 1999 ). Thus, GATA-1-mediated repression of PU.1 leads to a block in myeloid differentiation and could contribute to the malignant phenotype in some types of immature acute myeloid leukemia. Therefore, in order to prevent GATA-1-mediated repression of PU.1, we considered mutating the β3/β4 region of PU.1 so as to abolish its interaction with the repressor protein GATA-1. Here we have used a combined approach involving a detailed sequence and structural analysis of PU.1 protein followed by mutational analysis to identify PU.1 residues (in the β3/β4 region) critical for its interaction with GATA-1.
The molecular modeling and in silico docking techniques were used to study the specific molecular contacts between PU.1 and GATA-1 and to predict PU.1 mutants with reduced GATA-1 binding ability. The threedimensional (3D) models of both PU.1 and GATA-1 were generated though a fully automated comparative protein and GATA-1 using Hex 4.5 software (Fig. 2c) . This led us to identify amino acid residues in PU.1 that were thought to be critical for its physical interaction with GATA-1, viz. Lys237, Val238, Lys239 and Lys240.
Further, in order to identify the PU.1 residues specifically involved in this interaction out of the predicted ones, the sequence analysis was performed. A PIR BLAST search followed by CLUSTAL W (version 1.81) multiple alignment of PU.1 homologues revealed that the β3/β4 region in their DNA binding domain was highly conserved (Altschul et al., 1989; Higgins et al., 1996). However, certain residues were not so strictly conserved and such residues might be responsible for different functions in different proteins. For instance, in human Spi-B protein, Arg substituted the highly conserved Lys240. Spi-B is also an ETS family transcription factor that is most closely related to PU.1 in its DNA binding domain (Rey et al., 19) . Rekhtman et al have reported that Spi-B also interacts with GATA-1 but the interaction between them is much weaker than that between PU.1 and GATA-1. The weaker interaction between Spi-B and GATA-1 could be attributed to Arg240, which because of its bulky guanidinium group might cause steric hindrance to GATA-1. Hence, we predicted a mutation Lys240Arg in the β3/β4 region of PU.1 that would likely have reduced GATA-1 binding ability. We also decided to substitute Lys240 residue with Ala in order to determine whether a positively charged residue at this position is necessary for interaction with GATA-1. Since Ala is a small-sized uncharged amino acid residue, it would not affect the overall structural conformation of a protein.
Furthermore, only Tyr244 residue in the β3/β4 region of PU.1 was found to be significantly involved in intramolecular hydrogen bonding. In order to determine the role of Tyr244 in PU.1-GATA-1 interaction, we again performed protein-protein docking between GATA-1 and PU.1 mutant in which Tyr244 was substituted Ala (Fig.   2d ). We observed a significant change in intramolecular H-bond lengths in PU.1 mutant Tyr244Ala ( Table 4) . Such changes in the intramolecular H-bonding of PU.1 are likely to induce a change in the conformation of its β3/β4 region, which probably would disrupt its interaction with GATA-1. Therefore, a third mutation Tyr244Ala was predicted. In order to validate these predictions, the above-mentioned mutants were generated by PCR-based sitedirected mutagenesis and evaluated for enhanced myelopoiesis. The precise regulation of wild type PU.1 and its mutants in host cells is crucial as their deregulated overexpression would certainly lead to oncogenic conditions, thus necessitating the use of regulatable expression system. Therefore, prior to mutagenesis, wild type PU.1 was subcloned in an inducible mammalian gene expression vector, pTRE2 that uses a doxycycline-dependent transcriptional switch for controlling gene expression (Gossen et al., 1994; 1995).
A T-lymphoblast cell line Jurkat E6.1 that lacks endogenous expression of PU.1 was used to study the effects of regulated overexpression of PU.1 mutants. The wild type PU.1 as well as mutants were transfected and stable cell lines were made. Since the point mutations in PU.1 were made in its DNA binding domain (β3/β4 region), we determined the DNA binding ability of these mutants (Lys240Arg, Lys240Ala and Tyr244Ala) through electrophoretic mobility shift assay (EMSA). Double stranded oligonucleotides containing PU.1 consensus site in the M-CSF receptor promoter were used as probes, which were end-labeled with [- (Fig. 3a,c) . Thus DNA binding ability of PU.1 was not disrupted upon making mutations in its DNA binding domain. In order to determine the specificity of PU.1 protein for its DNA binding site, a competitive EMSA was performed using excess concentrations of unlabeled specific and non-specific probes (Fig. 3b) . On using 1:2 and 1:10 concentrations of labeled:unlabeled specific probe, no shift was observed because the excess of unlabeled specific probe competed with labeled specific probe. However, in case of non-specific probe, a clear shift was observed at both 1:2 and 1:10 concentrations, as the non-specific probe did not compete with labeled specific probe. These results suggest that PU.1 binds to its specific DNA binding site.
The effects of overexpression of wild type PU.1 and mutants in Jurkat E6.1 cells were determined by flow cytometry for myeloid-cell specific markers CD33 and CD116 (GM-CSF receptor α). An increase was observed in CD33 and CD116 expression in cells overexpressing wild type PU.1 and mutants after 72 h of induction, but there was no change in the expression of T-cell marker CD3. The maximum increase in CD33 expression was found in case of mutants Tyr244Ala (17% more than wild type PU.1) (P=0.05) and Lys240Arg (13%) (P=0.02) as compared to the wild type PU.1 (Fig. 4a,b) . Similarly, we found an increase in CD116 expression in cells overexpressing mutants Lys240Arg and Tyr244Ala by 45% (P<0.01) and 42% (P<0.01) respectively as compared to wild type PU.1 (Fig. 4c,d ). This suggests that the mutants Tyr244Ala and Lys240Arg have a higher potential of generating myeloid cells and this could be due to their weaker interaction with the interacting protein GATA-1. Interestingly, the overexpression of wild type PU.1 and its mutants had no effect on the expression of T-lymphocyte marker CD3, which is characteristic of Jurkat cells (Fig. 5) . This is in accordance with the previously established fact that expression of PU.1 gene is not required for the development of T-cells (Spain et al., 1999) .
We also assessed the effects of overexpression of wild type PU.1 and its mutants in CD34 + human hematopoietic stem cells (HSCs) isolated from bone marrow by determining their ability to express myeloid marker CD33 after 96 h of doxycycline induction. A slight increase was observed in the expression of CD33 in cells overexpressing wild type PU.1 and mutants Lys240Arg and Lys240Ala, but there was a significant (32%) (P<0.01) increase in CD33 expression in case of HSCs overexpressing mutant Tyr244Ala (Fig. 4e,f) . This suggests that the mutant Tyr244Ala has the highest potential for generating myeloid cells. This result is also in correlation with our in silico studies. The 6 structural changes inflicted on PU.1 by the mutation Tyr244Ala might be responsible for its reduced interaction with GATA-1 protein, which in turn might have led to an increase in the expression of myeloid marker CD33 in the HSCs expressing Tyr244Ala mutant.
Thus, we conclude that overexpression of PU.1 and its mutants Lys240Arg and Tyr244Ala increases myeloid lineage formation in human CD34 + progenitor cells as well as cells that are already committed to other lineages.
Therefore, we propose that PU.1 mutants Lys240Arg and Tyr244Ala have higher potential for myelopoiesis and this could be attributed to their reduced binding with the repressor protein GATA-1. Further studies such as colony formation assays will define more precisely the mechanism underlying PU.1 and GATA-1 antagonism as well as enhanced myeloid lineage formation ability of PU.1 mutants and ultimately may lead to the development of approaches for better differentiation therapy.
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